(Q30401982)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

J Garcia-Sicilia

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

P Gillard

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

A Carmona

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

J Aristegui

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

J M Merino

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

U Behre

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

A Caplanusi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

T Vaman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

I Dieussaert

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

English

0 references

publication date

17 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

4353-4361

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21504774%20AND%20SRC:MED&resulttype=core&format=json

Critically Ill patients with 2009 influenza A(H1N1) in Mexico

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Pandemic potential of a strain of influenza A (H1N1): early findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

A new decade, a new seasonal influenza: the Council of the European Union Recommendation on seasonal influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Critically ill patients with 2009 influenza A(H1N1) infection in Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Emergence of a novel swine-origin influenza A (H1N1) virus in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

2009 influenza A(H1N1) monovalent vaccines for children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Efficacy and effectiveness of influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Protective effect of single-dose adjuvanted pandemic influenza vaccine in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

A novel influenza A (H1N1) vaccine in various age groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011

Evaluation of the safety and immunogenicity of pneumococcal seven-valent conjugate vaccine (Prevenar) administered in previously unvaccinated Spanish children aged 24 to 36 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.011